Publications by authors named "Faye M Feller"
Article Synopsis
- * The phase III trial, IMpactMF, will compare imetelstat to the best available therapies (excluding JAK inhibitors) in these refractory MF patients.
- * The trial will administer imetelstat via IV every 21 days, focusing on overall survival as the main goal, while also examining additional effects such as symptom relief, spleen size, and safety.
J Clin Oncol
September 2021
Article Synopsis
- Myelofibrosis patients who don't respond to JAK inhibitors have a poor survival rate of about 13-16 months; a phase II study was conducted to evaluate the telomerase inhibitor imetelstat in these patients.
- In this study, patients received either 9.4 mg/kg or 4.7 mg/kg of imetelstat to assess responses in spleen size reduction and symptom improvement, with results showing better outcomes for the higher dose.
- The higher dose (9.4 mg/kg) led to a median overall survival of 29.9 months and significant benefits in symptom relief, despite common side effects like reversible cytopenias, prompting further phase III studies.
